Theralizumab

N/A

Report date: 2024/08/13 20:00:09

Base Information

Drug NameTheralizumab
Drug Alias NameTAB-08TABO-8
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAnti-CD28T lymphocytes stimulants
TargetsT-cell-specific surface glycoprotein CD28
Therapy Area/IndicationsSolid tumoursPsoriasisLupus Erythematosus, Systemic +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryRussian Federation
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTheramab Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTheramab Llc
Active IndicationsN/A
Inactive IndicationsSolid tumoursPsoriasisLupus Erythematosus, Systemic +[5] 

Other Information

ATC CodeN/A
Related LinksN/A